Screener
Oruka Therapeutics, Inc. ORKA Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (36,434) | (25,086) |
| Other income (expense): | ||
| Interest income | 4,606 | 4,092 |
| Other income (expense), net | 8 | (5) |
| Total other income, net | 4,614 | 4,087 |
| Net loss | $(31,820) | $(20,999) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.48) | $(0.40) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(39.81) | $(32.95) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s other income, net (note 6)?
- Oruka Therapeutics, Inc. (ORKA) reported other income, net (note 6) of $8K in Q1 2026.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Oruka Therapeutics, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude